Allogene Therapeutics, Inc.
Allogene Therapeutics is a U.S. clinical-stage biotechnology company developing allogeneic, or donor-derived, engineered cell therapies. Its AlloCAR T approach aims to develop off-the-shelf cellular medicines, using gene engineering and specialized cell-manufacturing methods. Research focuses on cancer and selected autoimmune diseases, while development programs evaluate the safety and activity of different cellular constructs. The company is based in South San Francisco, California, and its common stock trades on Nasdaq under ALLO. This entry identifies the company's therapeutic modality and disease areas without treating evolving clinical results as permanent facts.
Company at a glance
Corporate information
- Company entity
- Allogene Therapeutics, Inc.
- Headquarters / principal office
- United States
- Founded
- Not verified
- Ownership / capital status
- Publicly tradedPublicly listed
- Official corporate reference
- https://www.allogene.com/
- LinkedIn company page
- Independent company page not verified
Profile review: 2026-11-08 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Listed issuer and R&D focus
Nasdaq: ALLO
allogeneic CAR-T · engineered cell therapy
oncology · autoimmune disease
Last independently verified:
Disease tags match recorded text mentions and require program-level verification.
Technology, programs & evidence
Allogene Therapeutics is a U.S. clinical-stage biotechnology company developing allogeneic, or donor-derived, engineered cell therapies. Its AlloCAR T approach aims to develop off-the-shelf cellular medicines, using gene engineering and specialized cell-manufacturing methods. Research focuses on cancer and selected autoimmune diseases, while development programs evaluate the safety and activity of different cellular constructs. The company is based in South San Francisco, California, and its common stock trades on Nasdaq under ALLO. This entry identifies the company's therapeutic modality and disease areas without treating evolving clinical results as permanent facts.
Business, technology & evidence
- SecuritiesNasdaq: ALLO
Individual program detail is not recorded. Consult the original sources below.
Related news & literature
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
Showing 0 / 0 related items
No cataloged update explicitly mentions this company.
Same-field reading (not company-specific)
Research this company together
Discussions are for signed-in members. Personal notes remain separate from company research.
Sign in to joinSources & open questions
- Official issuer and R&D disclosure · Allogene Therapeutics, Inc. ↗Allogene Therapeutics, Inc. ·
- Official issuer and R&D disclosure · Allogene Therapeutics, Inc. ↗Allogene Therapeutics, Inc. ·
Inclusion is not endorsement or partner qualification. Assess company claims, clinical evidence, and project-specific capabilities separately.